Featured Research

from universities, journals, and other organizations

Molecular Pathway May Predict Chemotherapy Effectiveness

Date:
September 3, 2007
Source:
University of Cincinnati
Summary:
A common molecular pathway could help physicians predict which lung cancer patients will benefit from chemotherapy drugs, according to new research. Known as the retinoblastoma (RB) tumor suppressor, this fundamental molecule regulates cell proliferation in the body. Research has shown that the RB pathway is either entirely inactive or altered in most human cancers. Scientists are beginning to use its actions as a "biomarker" for how tumors will respond to different therapies. Now researchers have found that "turning off" the RB pathway in lung cancer cells resulted in an altered response to chemotherapy agents and more cancer cell death.

Michael Reed, MD, and William Zagorski of UC's surgery department study the role of the RB tumor suppressor in lung cancer.
Credit: Image courtesy of University of Cincinnati

A common molecular pathway could help physicians predict which lung cancer patients will benefit from chemotherapy drugs, according to new research from a multidisciplinary team at the University of Cincinnati (UC).

Related Articles


Known as the retinoblastoma (RB) tumor suppressor, this fundamental molecule regulates cell proliferation in the body. Research has shown that the RB pathway is either entirely inactive or altered in most human cancers. Scientists are beginning to use its actions as a "biomarker" for how tumors will respond to different therapies.

Michael Reed, MD, and his UC colleagues found that "turning off" the RB pathway in lung cancer cells resulted in an altered response to chemotherapy agents and more cancer cell death. They report their findings in the September 2007 issue of the journal Cancer Research.

"Dissecting the RB pathway will help us better understand how chemotherapy works and predict which patients might benefit from therapy and which ones won't," explains Reed, assistant professor of surgery at UC and a thoracic surgeon at University Hospital.

"As pathways are further defined, we could choose agents that are targeted to an individual tumor's molecular characteristics," he adds.

A previous UC study, published in the January 2007 issue of the Journal of Clinical Investigation, showed that when this pathway is disrupted or shut off in breast cancer, the tumor resists anti-estrogen drugs and the cancer continues to grow in spite of the therapy.

For this laboratory study, Reed's team shut off the RB pathway in human non-small cell lung cancer cells and exposed them to chemotherapy agents representative of those currently used to treat lung cancer patients.

Their results showed that when RB was turned off, the cancer cells continued to divide, but became more susceptible to the drugs, so the tumors stopped growing.

"But the minute you take away the chemotherapy, the cells take off again," says Reed. "This suggests that it's not just loss of RB that affects therapy response--it could be changes at various steps in cellular signaling that result in different outcomes."

"The traditional way of thinking of cancer--one cancer gene to treat and you're done--is obviously not the best approach to treating this disease," he adds. "These are complex, overlapping molecular pathways. Dissecting them and determining how to use that information to apply combinations of chemotherapeutic agents will allow for individualization of therapy."

Next year, Reed and his colleagues expect to begin testing the RB tumor suppressor in human tumor tissue samples from the UC Thoracic Tumor Registry and compare them to patients with known outcomes.

According to the American Cancer Society, more than 213,000 Americans will be diagnosed with lung cancer in 2007. Because most people are diagnosed late, the five-year survival rate is only 14 percent--compared with 86 percent for breast cancer, 61 percent for colon cancer and 96 percent for prostate cancer.

This study was funded by a grant from the National Institutes of Health and UC College of Medicine Dean's Discovery Fund and the UC cancer research program. UC study collaborators include Erik Knudsen, PhD, and William Zagorski.


Story Source:

The above story is based on materials provided by University of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati. "Molecular Pathway May Predict Chemotherapy Effectiveness." ScienceDaily. ScienceDaily, 3 September 2007. <www.sciencedaily.com/releases/2007/09/070901073610.htm>.
University of Cincinnati. (2007, September 3). Molecular Pathway May Predict Chemotherapy Effectiveness. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2007/09/070901073610.htm
University of Cincinnati. "Molecular Pathway May Predict Chemotherapy Effectiveness." ScienceDaily. www.sciencedaily.com/releases/2007/09/070901073610.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins